Risk of seizure in patients with prostate cancer treated with enzalutamide in China: a noninterventional study
Among patients with PC in China, the risk of seizure was low in both the enzalutamide and alternative antiandrogen groups, despite the presence of risk factors for seizure in over one-third of patients.
Authors
- Zu Ying
- Bing Hu (ORCID: https://orcid.org/0000-0001-8627-5272)
- Siyi He (ORCID: https://orcid.org/0000-0001-7812-997X)
- Qian Xiang (ORCID: https://orcid.org/0000-0002-8245-2611)
- Xingbo Long (ORCID: https://orcid.org/0000-0002-5918-687X)
- Yonghong Li (ORCID: https://orcid.org/0000-0002-1795-7242)
- Yadong Cui
- Yuanjie Niu (ORCID: https://orcid.org/0009-0000-6513-5940)
- Shaobin Wei (ORCID: https://orcid.org/0000-0001-7464-4683)
- Mei Yang (ORCID: https://orcid.org/0000-0003-1741-1853)
- N. Robinson (ORCID: https://orcid.org/0009-0005-2064-8925)
- Nan Sun (ORCID: https://orcid.org/0000-0003-4722-6261)
- Qingpeng Xie
- Yong Wang (ORCID: https://orcid.org/0000-0003-0695-5273)
Institutions
- Astellas Pharma (Japan) (JP)
- Sun Yat-sen University (CN)
- Astellas Pharma (China) (CN)
- Second Hospital of Tianjin Medical University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Astellas Pharma (United States) (US)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/20420986251391078
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00